Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Infants by Use of Dried Blood Spots and an Ultrasensitive p24 Antigen Assay by Cachafeiro, A. et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2009, p. 459–462 Vol. 47, No. 2
0095-1137/09/$08.000 doi:10.1128/JCM.01181-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Diagnosis of Human Immunodeficiency Virus Type 1 Infection in
Infants by Use of Dried Blood Spots and an Ultrasensitive p24
Antigen Assay
Ada Cachafeiro,1 Gayle G. Sherman,2 Annette H. Sohn,3
Consuelo Beck-Sague,4 and Susan A. Fiscus1*
Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina1; Department of
Molecular Medicine and Haematology, University of Witwatersrand, Johannesburg, South Africa2; Division of Pediatric Infectious Diseases,
University of California, San Francisco, San Francisco, California3; and Clínica de Familia MIR, La Romana, Dominican Republic4
Received 22 June 2008/Returned for modification 27 September 2008/Accepted 3 December 2008
We tested 617 dried blood spots (DBS) from human immunodeficiency virus-exposed infants from five
countries using an ultrasensitive p24 antigen assay (Up24). The sensitivity was 94.4% (67/71) and the speci-
ficity was 100% (431/431) for infants with DBS specimens <20 months old; DBS older than 30 months
demonstrated only 72.2% sensitivity (39/54) (P < 0.001) but displayed 100% specificity (61/61).
Several factors reduce diagnosis of human immunodefi-
ciency virus (HIV) in infancy in resource-limited settings. Sim-
ple, rapid antibody assays cannot be used because of the pres-
ence of maternal antibodies. As a consequence, viral nucleic
acids or proteins must be detected. Nucleic acid assays are
technologically complex and subject to contamination and re-
quire expensive equipment and highly trained technologists,
limiting availability to selected centers of excellence in re-
source-limited countries (1, 8, 12, 15, 28, 30).
The ultrasensitive p24 antigen assay (Up24), an alternative
that overcomes the limitations of antibody assays while using
an enzyme-linked immunosorbent assay (ELISA)-based plat-
form, reduces the need for expensive equipment and person-
nel. It has been used successfully with plasma for over 12 years
for diagnosis of HIV infection in infants (9, 11, 13, 18, 19, 26,
29, 32).
Another factor limiting diagnosis of HIV infection in infants
is the need for phlebotomy to collect specimens and cold chain
maintenance while the specimen is transported to a central
laboratory. These have been addressed by adaptation of nu-
cleic acid (2–7, 10, 16, 20, 21, 27, 31), and now Up24 antigen
assays, for use with dried blood spots (DBS) (14, 22, 23).
Other investigators have adapted the Up24 assay for use
with DBS. Table 1 compares these different extraction meth-
ods used for p24 antigen assays with DBS. Li et al. (17),
following the manufacturer’s instructions for plasma speci-
mens, reported 0% specificity using DBS. Knuchel et al. (14)
improved the sensitivity by modifying the elution buffer (25)
and increased specificity to 100% by adding a quenching step
using hydrogen peroxide after the first wash. Patton et al. (22,
23) improved elution by using the previously described buffer
(25) and 0.5% Triton X-100. The reported sensitivity and spec-
ificity were 98.3 to 98.8% and 100%, respectively. Our objec-
tives were to develop and optimize a simpler method for HIV
infant diagnosis using DBS and reagents found in commer-
cially available Up24 test kits as much as possible and to assess
the optimized assay performance.
(This work was presented in part at the CDC Conference on
HIV Diagnostics, Atlanta, GA, 5 to 7 December 2007, and the
15th Conference on Retroviruses and Opportunistic Infec-
tions, Boston, MA, 2 to 6 February 2008.)
DBS obtained from patients in the Dominican Republic
(n  60), Malawi (n  9), South Africa (n  210), United
States (n  264), and Vietnam (n  74) were collected on
Whatman 903 paper (Whatman, Sanford, ME), air dried,
stored with a desiccant in individual ziplock bags at room
temperature (Dominican Republic, South Africa, and Malawi)
or at 4 to 8°C (Vietnam) or at 20°C (United States), and
shipped to the laboratory at the University of North Carolina,
Chapel Hill (UNC). The infants had been previously tested for
HIV type 1 (HIV-1) either by DNA PCR using cell pellets
from whole blood using the Roche Amplicor assay, version 1.5
(Branchburg, NJ) for specimens from the United States and
South Africa or an in-house HIV DNA assay (Pasteur Insti-
tute, Ho Chi Minh City, Vietnam) for specimens from Viet-
nam. Specimens from Malawi and the Dominican Republic
were originally tested as DBS using an HIV RNA assay (Nu-
cliSens QT; bioMerieux, Durham, NC). These results were
considered the gold standard against which the DBS Up24
antigen results were compared. All infected infants had fol-
low-up specimens to confirm HIV infection.
Most U.S. infants were receiving 6 weeks of zidovudine
prophylaxis at the time of sampling. All Malawian infants had
received a single dose of nevirapine and 1 week of zidovudine
and lamivudine. Some Vietnamese and South African children
were beyond infancy and known to be HIV infected. In addi-
tion, DBS from South African infants had been tested in a
previous Up24 assay study (23). DBS 30 months old were
evaluated separately.
Controls were prepared from non-HIV-1-infected whole
blood samples. Negative controls consisted of 50-l spots of
whole blood on Whatman 903 paper. Positive-control DBS
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were prepared by adding the PerkinElmer HIV-1 ELISA pos-
itive control to normal whole blood to a titer of 100 pg/ml. The
control DBS were air dried and stored in ziplock bags at 20°C
with a desiccant sachet and a humidity indicator card (Static
Control Components, Inc., Sanford, NC).
Two 6-mm disks were punched from the DBS using an
ordinary paper puncher cleaned between samples and placed
in 1.5-ml screw-cap Sarsted tubes (Newton, NC). The disks
were incubated for 10 min at room temperature with 50 l of
a specimen preparation buffer consisting of the PerkinElmer
HIV-1 core profile ELISA standard/sample diluent in the
ELAST amplification kit NEP116VL (PerkinElmer Life Sci-
ences, Boston, MA) with the addition of 10 mM EDTA and 30
mM Tris-HCl, pH 7.2. The elution buffer consisted of 9 parts
of 0.5% Triton X-100 diluted 1:10 in PBS and 1 part (vol/vol)
of Tris reagent. The PerkinElmer kit includes both Tris-HCl
and Triton X-100. After the addition of 0.25 ml of the elution
buffer, the DBS disks were rocked overnight at 4°C and re-
moved from the sample using wooden sticks. The tubes were
transferred to a heat block, boiled for 5 min at 100°C, and
allowed to cool for 10 min. The Up24 protocol in the ELAST
amplification kit was subsequently followed except that instead
of using the QuantiKin software to read the assay, an endpoint
reading at two wavelengths of 490 and 650 nm was obtained
after 30 min of substrate incubation. Four methods of calcu-
lating a cutoff were explored. The cutoff selected (mean optical
densities of two negative controls plus 0.05) provided the best
correlation for the data. Samples with optical densities greater
than that number were considered positive. All specimens were
tested once. Repeat tests were performed on several speci-
mens; the result was always concordant with the first. UNC
testing personnel were blinded as to the infant’s infection
status.
Of 617 DBS from HIV-exposed infants assessed, 324 were
presumed to be subtype B and came from the United States
and Dominican Republic; 219 from Malawi and South Africa
were presumed to be subtype C, and 74 from Vietnam were
presumed to be subtype A/E. DBS that were 20 months old
were evaluated with the optimized assay and compared to their
respective gold standard (Table 2). Among the 431 true neg-
ative specimens, there were no false-positive results (100%
specificity). The sensitivity of the assay increased from 50%
within the first week of life to 80% for infants 1 to 6 weeks old
to 95% for infants and children 6 weeks old. Both false-
negative results in the youngest age group were from Malawian
infants receiving zidovudine-lamivudine-nevirapine for pre-
vention of mother-to-child transmission. The false-negative
specimen in the 1- to 6-week age group was from a 3-week-old
U.S. infant receiving zidovudine prophylaxis. The false-nega-
tive result for the 6- to 26-week age group was from a 14-week-
old infant from the Dominican Republic who was not receiving
prophylaxis. Patton et al. (22, 23) never tested neonates in the
TABLE 1. Comparison of different extraction methods used for p24 antigen assays with DBSa
Assay details Li et al. (17) Patton et al. (22, 23) Knuchel et al. (14) This study
Steps in procedure 1. Elute 50 l DBS using
0.5% Triton X-100
1. Incubate duplicate 6-mm
punches with 25 l SNCR
bufferb for 10 min at
room temp
1. Combine 16-mm DBS
plus 0.8 ml of elution
buffer (1 part SNCR
buffer, 1 part water,
and 9 parts of 0.5%
Triton X-100)
1. Incubate duplicate 6-mm
punches with 50 l
specimen preparation
bufferc for 10 min at
room temp
2. Incubate 60 min 2. Add 275 l of 0.5%
Triton X-100
2. Incubate on a shaker/
rocker 8 h at room
temp
2. Add 0.25 ml of 9 parts of
0.5% Triton X-100
diluted in PBS to 1 part
of Tris reagent
3. Centrifuge 13,600  g for
3 min
3. Incubate overnight at 4°C 3. Boil for 5 min at 100°C 3. Shake for 2 h at room
temp or overnight at 4°C
4. Transfer to a screw-cap
cryovial and boil for 5
min at 100°C




4. Boil for 5 min at 100°C
5. Proceed with the standard
Up24 antigen assay
protocol
5. Proceed with the
standard Up24 antigen
assay protocol
5. After the first wash,
quench with 0.3% H2O2
in 50 mM Tris-HCl for
10 min at 37°C
5. Proceed with the
standard Up24 antigen
assay protocol
6. Continue with the
standard Up24 antigen
assay protocol
Assay times 8 h 4 to 5 h on day 1, overnight
incubation, 4 h on day 2
9 h on day 1, overnight
incubation, 3 h on
day 2
1 h on day 1, overnight
incubation, 4 to 5 h on
day 2
Sensitivity (%) 96 if viral load 1,000
copies/ml
98.3–98.8 84 94.4
Specificity (%) 0 100 100 100
a Reagents in boldface type were not included in the manufacturer’s kit.
b SNCR buffer consists of 30 mM Tris-HCl (pH 7.2), 450 mM NaCl, 1.5% Triton X-100, 1.5% deoxycholic acid, 0.3% sodium dodecyl sulfate, and 10 mM EDTA.
c Specimen preparation buffer consists of kit specimen diluent, 10 mM EDTA, and 30 mM Tris-HCl (pH 7.2).
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first week of life (the youngest was 20 days old). If the age
group within the first week of life is excluded, the sensitivity is
97% (65/67).
Among 115 DBS from South Africa that had been tested
previously and then stored at room temperature for 30
months (23), there was a trend toward decreasing sensitivity as
the age of the infant increased, although it was not significant
(P  0.12); the sensitivity was 100% (3/3) for DBS from infants
1 and 6 weeks old, while it was 66% (21/32) for infants of
72 weeks of age (Table 2). The specificity was 100% across all
age groups. Some older infants and children may have been on
antiretroviral treatment at the time of collection, but no treat-
ment data were collected.
Our aim was to simplify the procedure and maximize the use
of the reagents already in the manufacturer’s kit. The final
optimized procedure used a specimen preparation buffer that
contained only two reagents not found in the kit—10 mM
EDTA and 30 mM Tris-HCl. We have now tested this proce-
dure on 617 DBS from HIV-exposed infected and uninfected
infants and children. The assay demonstrated 94.4% sensitivity
for diagnosis of HIV infection with presumed HIV-1 subtypes
B, C, and AE (n  502) using DBS 20 months old versus
72.2% in older specimens (P  0.001), achieving 100% speci-
ficity without complicating the procedure with a quenching
step.
This is the largest series of infants 7 days of age tested
using the Up24 assay using DBS. Although the sensitivity was
only 50% (2/4), the specificity was 100% (80/80). Others have
suggested that p24 assays might be less specific in very young
infants (24). However, we previously tested plasma samples
with the Up24 assay and observed similar specificity in infants
0 to 7 days of age (1 of 109 [99%]) (11). The optimal time to
use the Up24 antigen assay for infant diagnosis requires fur-
ther investigation, especially as prevention of mother-to-child
transmission programs in low-resource countries move to
more-complex and longer postdelivery antiretroviral regimens.
The lengths of storage time and temperatures varied, de-
pending on the original collection site (country), but did not
appear to affect assay sensitivity when specimens were tested
within 20 months of collection, in contrast to data suggesting
that DBS should be tested within 6 weeks of collection if
Whatman no. 1 filter paper was used (22). When Whatman 903
was employed (as done here), little loss of sensitivity was ob-
served at 12 weeks. In most cases, samples are tested within a
few weeks of collection. DBS from infants 6 to 26 weeks of age
demonstrated 94.5% sensitivity and 100% specificity, regard-
less of the length of room temperature storage (up to 20
months); 72% of DBS stored more than 30 months at room
temperature still had detectable antigen using the optimized
Up24 assay.
Our results confirm that infant HIV infection can be accu-
rately diagnosed using DBS and an optimized Up24 antigen
assay, with lower cost and less complexity.
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